Skip to content
glimepiride

Structure via PubChem · Public domain (PubChem)

EntityQ106029845· pop 30· linked from 680 articles

glimepiride

Sign in to save

Also known as 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide, 3-ethyl-4-methyl-N-[4-(N-{[(1r,4r)-4-methylcyclohexyl]carbamoyl}sulfamoyl)phenethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide

Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.

Chemical data

Formula
C24H34N4O5S
Molecular weight
490.6 g/mol
IUPAC name
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
SMILES
CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
InChIKey
WIGIZIANZCJQQY-UHFFFAOYSA-N
XLogP
3.9
Polar surface area
133 Ų
H-bond donors
3
H-bond acceptors
5
Formal charge
0

via PubChem

Research

1,852 papers

via PubMed

~6 min read

Encyclopedic overview

7 sections
Contents
  • Medical uses
  • Contraindications
  • Adverse effects
  • Interactions
  • Mechanism of action
  • Pharmacokinetics
  • References

{{drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 412761821 | image = Glimepiride.svg | image_class = skin-invert-image | width = 300 | alt = | image2 = Glimepiride ball-and-stick model from xtal 1997.png | image_class2 = bg-transparent

| tradename = Amaryl, others | Drugs.com = | MedlinePlus = a696016 | DailyMedID = Glimepiride | pregnancy_AU = C | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BB12 | ATC_supplemental =

Excerpted from Wikipedia’s “glimepiride” article, available under the CC BY-SA 4.0 licence.

Gallery (3)